Oncology
Ovary Cancer
3
Pipeline Programs↗
2
Active Trials↗
1
Companies Involved↗
Ovary Cancer is an early-stage landscape with 3 programs across 1 company. The most active players are AstraZeneca.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 23
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
2programs
Small molecule150%
Antibody–drug conjugate150%
Modality classified for 67% of 3 pipeline programs.
Analysis
Trial Status
4
clinical trials
Recruiting2 · 50%
Completed1 · 25%
Unknown status1 · 25%
Clinical Trials
Trial Activity
Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer
Unknown status·—·Phase 2/3·NCT02159820·500 enrolled
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer
Recruiting·—·Phase 2·NCT07667751·35 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)